Hemp-Derived Cannabinoids Panel - CannMed 25 Innovation & Investment Summit

Tags: Hemp-Dervied Cannabinoids, Derived Cannabinoids, HDCs, THCA, Hemp Products, Hemp Product Safety

Moderator: Jean E. Smith-Gonnell ​ (‪@troutmanpepperlockellp‬)
Panelists: Mark A. Scialdone, PhD (BetterChem Consulting) , Michelle Peace, PhD (‪@virginiacommonwealthuniversity‬), Mike Hennesy (‪@wanabrands9237‬)

The rapid rise of hemp-derived cannabinoids (HDCs) has created a new space in cannabinoid research and commerce, offering new therapeutic potentials and market opportunities and controversies. This fast-growing sector also faces critical challenges, including significant gaps in state and federal regulations and the presence of irresponsible actors exploiting legal loopholes. These issues raise concerns about consumer safety, product integrity, and the long-term viability of the industry.

This panel unites scientists, policymakers, and legal professionals to provide a comprehensive exploration of the HDC landscape, emphasizing both its promise and its pitfalls. Attendees will learn about the latest research on the pharmacology and therapeutic potential of HDCs, alongside a frank discussion of the risks posed by unregulated products, misleading marketing practices, and inconsistent quality standards.

Learn More about CannMed: https://cannmedevents.com/
Sign Up for Our Newsletter: https://share.hsforms.com/1oi57oJDnRN...

0:00 Intro & Welcome
0:45 Panelist Introductions
5:20 Farm Bill Loopholes Explained
12:15 Chemistry of CBD Conversions
18:40 Safety & Public Health Concerns
25:10 Youth Access & Vaping Issues
33:00 Regulatory Gaps & State Bans
42:30 Industry Risks & Market Impact
51:15 Federal Legalization & Policy Outlook
54:00 Closing Thoughts & Takeaways

The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.